TST: A Protein with Potential as A Drug Target Or Biomarker (G7263)

Target Name: TST

NCBI ID: G7263

Content of Review Report on TST Target / Biomarker

TST

TST: A Protein with Potential as A Drug Target Or Biomarker

TST (Tumor suppressant protein) is a protein that is found in the human body and has been shown to have potential as a drug target or biomarker in the treatment of various diseases. TST is a transmembrane protein that is involved in the inhibition of cell proliferation and has been shown to play a role in the development and progression of several types of cancer.

One of the main functions of TST is its ability to inhibit the activity of the kinases that are involved in cell proliferation. These kinases include several different types, including the B-cell lymphoma 1 (BCL-1) kinase, which is known to be a key driver of cancer cell proliferation. TST has been shown to inhibit the activity of BCL-1 in a variety of cell types, including cancer cells, and has been shown to have potential as a drug target for cancer treatment.

Another function of TST is its ability to induce cell apoptosis, which is the process by which cells die naturally. This process is important for the elimination of damaged or dysfunctional cells and is a key aspect of the immune system's response to cancer. TST has been shown to induce cell apoptosis in a variety of cell types, including cancer cells, and has been shown to have potential as a drug target for cancer treatment.

In addition to its functions as a drug target and biomarker, TST has also been shown to have potential as a therapeutic agent for a variety of other conditions. For example, TST has been shown to have potential as a treatment for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, due to its ability to induce cell apoptosis and protect against neurotoxicity. TST has also been shown to have potential as a treatment for ischemia-induced pain, due to its ability to protect against ischemia-induced neuroinflammation and improve blood flow to the affected area.

Despite its potential as a drug target and biomarker, TST is still in the early stages of research and has not yet been approved for use by the FDA or any other regulatory agency. Further studies are needed to fully understand the potential of TST as a drug and to determine the best way to use it in the treatment of various diseases.

In conclusion, TST is a protein that has been shown to have potential as a drug target and biomarker in the treatment of various diseases. Its ability to inhibit cell proliferation and induce cell apoptosis makes it a promising candidate for cancer and other therapeutic applications. Further research is needed to fully understand the potential of TST and to determine the best way to use it in the treatment of diseases.

Protein Name: Thiosulfate Sulfurtransferase

Functions: Formation of iron-sulfur complexes, cyanide detoxification or modification of sulfur-containing enzymes. Other thiol compounds, besides cyanide, can act as sulfur ion acceptors. Also has weak mercaptopyruvate sulfurtransferase (MST) activity (By similarity). Together with MRPL18, acts as a mitochondrial import factor for the cytosolic 5S rRNA. Only the nascent unfolded cytoplasmic form is able to bind to the 5S rRNA

The "TST Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TST comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets